AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30796110 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy (10,000 lux)
Number of subjects: 83
Study 30796110 — intervention group
Group type: COMPARATOR
Intervention: Placebo light therapy
Number of subjects: 83
Study 28280882 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 155
Study 28280882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 26125807 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition starting 1 week before surgery
Number of subjects: 200
Study 26125807 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition starting early after surgery
Number of subjects: 200
Study 23280459 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered planning and collaborative documentation
Number of subjects: 367
Study 23280459 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 367
Study 21980992 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin-depleting LNAA mixture
Number of subjects: 15
Study 21980992 — intervention group
Group type: COMPARATOR
Intervention: Protein control (PC) LNAA mixture
Number of subjects: 15
Study 18298873 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 42
Study 18298873 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-N2O
Number of subjects: 42
Study 16795979 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 dissection (N = 128)
Number of subjects: 256
Study 16795979 — intervention group
Group type: EXPERIMENTAL
Intervention: D4 dissection (N = 128)
Number of subjects: 256
Study 16795979 — intervention group
Group type: EXPERIMENTAL
Intervention: D4 dissection plus pancreatosplenectomy
Number of subjects: 256
Study 16795979 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 dissection plus pancreatosplenectomy
Number of subjects: 256
Study 16795979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both D2 and D4 groups
Number of subjects: 256
Study 12599240 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (4.5 microg/kg per week for 4 weeks, then 2.25 microg/kg per week for 8 weeks)
Number of subjects: 127
Study 12599240 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (4.5 microg/kg per week for 4 weeks, then 3.0 microg/kg every 2 weeks)
Number of subjects: 127
Study 12599240 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (4.5 microg/kg per week until hemoglobin concentration >or= 12 g/dL, then 1.5 microg/kg per week)
Number of subjects: 127
Study 12599240 — intervention group
Group type: COMPARATOR
Intervention: rHuEPO (40,000 U with escalations to 60,000 U for nonresponders)
Number of subjects: 127
Study 10905680 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 60
Study 10905680 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 60
Study 10905680 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 9354343 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 77
Study 9354343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 8473547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg once daily
Number of subjects: 9
Study 8473547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once daily
Number of subjects: 9
Study 8473547 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 3006368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mackerel diet
Number of subjects: 14
Study 3006368 — intervention group
Group type: COMPARATOR
Intervention: Herring diet
Number of subjects: 14
Study 31072970 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Number of subjects: 92
Study 31072970 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 92
Study 31072970 — intervention group
Group type: COMPARATOR
Intervention: Medical Management
Number of subjects: 92
Study 30139771 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (40% inspired)
Number of subjects: 36
Study 30139771 — intervention group
Group type: COMPARATOR
Intervention: Sham (air)
Number of subjects: 36
Study 27193497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg/day)
Number of subjects: 100
Study 27193497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24672935 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood activating water relieving method (BAWRM)
Number of subjects: 64
Study 24672935 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medical treatment (Control)
Number of subjects: 64
Study 23037460 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg intravenously before CECT imaging
Number of subjects: 209
Study 23037460 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hydration strategy)
Number of subjects: 209
Study 20484704 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced listeners (5 otolaryngologists and 5 speech-language pathologists)
Number of subjects: 21
Study 20484704 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced listeners (medical professionals with no formal training in voice disorders)
Number of subjects: 21
Study 19091932 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week online self-management education and peer support program
Number of subjects: 30
Study 14766488 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-whole practice (100 repetitions of the 8-element sequence on Day 1 and 100 repetitions of the 16-element sequence on Day 2)
Number of subjects: 18
Study 14766488 — intervention group
Group type: COMPARATOR
Intervention: Whole-practice (100 repetitions of the 16-element sequence on both days)
Number of subjects: 18
Study 12206794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of dystrophin cDNA
Number of subjects: 9
Study 9667605 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary MAD deficiency
Number of subjects: 0
Study 9667605 — intervention group
Group type: COMPARATOR
Intervention: Primary MAD deficiency
Number of subjects: 0
Study 9667605 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study 7907098 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic withdrawal (n = 64)
Number of subjects: 271
Study 7907098 — intervention group
Group type: COMPARATOR
Intervention: Continued use of antipsychotics (n = 207)
Number of subjects: 271
Study 2510253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil (300 micrograms)
Number of subjects: 21
Study 2510253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil (600 micrograms)
Number of subjects: 21
Study 2510253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30857258 — intervention group
Group type: EXPERIMENTAL
Intervention: Shellfish gatherers with more than 26 years of work experience
Number of subjects: 209
Study 30857258 — intervention group
Group type: EXPERIMENTAL
Intervention: Shellfish gatherers more exposed to work sitting with trunk flexion
Number of subjects: 209
Study 30857258 — intervention group
Group type: EXPERIMENTAL
Intervention: Shellfish gatherers performing manual handling and muscle force with the arms
Number of subjects: 209
Study 28235817 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of posterior limb of internal capsule
Number of subjects: 2066
Study 28235817 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of thalamus
Number of subjects: 2066
Study 28235817 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of infratentorial sites
Number of subjects: 2066
Study 28235817 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH encompassing thalamus and posterior limb of internal capsule
Number of subjects: 2066
Study 25896283 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise lifting (5 kg load increased by 2 kg every 2 min until fatigue)
Number of subjects: 20
Study 25896283 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise lifting
Number of subjects: 20
Study 24436950 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal nonsurgical treatment including oral hygiene instruction and scaling and root planing
Number of subjects: 75
Study 24436950 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instruction only
Number of subjects: 75
Study 21688877 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 310
Study 21688877 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Feedback Control (EFC)
Number of subjects: 310
Study 21688877 — intervention group
Group type: COMPARATOR
Intervention: Delayed Feedback Control (DFC)
Number of subjects: 310
Study 21688877 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (MET, EFC, DFC)
Number of subjects: 310
Study 18279406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ICE monitoring
Number of subjects: 82
Study 18279406 — intervention group
Group type: COMPARATOR
Intervention: Electronic ICE monitoring
Number of subjects: 82
Study 18279406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 17062645 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie Approach (McK)
Number of subjects: 315
Study 17062645 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Finding Approach (SFA)
Number of subjects: 315
Study 17062645 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 315
Study 12894866 — intervention group
Group type: EXPERIMENTAL
Intervention: Video reinforcement (moving images generated by a digital video disc player/monitor)
Number of subjects: 40
Study 12894866 — intervention group
Group type: COMPARATOR
Intervention: Conventional reinforcement (animated mechanical toy)
Number of subjects: 40
Study 16737346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 501
Study 16737346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 501
Study 10580352 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide (600 lipoprotein lipase releasing units [LRU] by im route per day for 30 consecutive days, followed by 500 LRU by oral route per day for a further 30 days)
Number of subjects: 94
Study 10580352 — intervention group
Group type: COMPARATOR
Intervention: standard treatment (cleansing with physiological solution and elastic compression with short‐extensibility, removable bandages)
Number of subjects: 94
Study 9772600 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinjikang capsule (XJK)
Number of subjects: 94
Study 9772600 — intervention group
Group type: COMPARATOR
Intervention: Metoprolo (Control)
Number of subjects: 94
Study 1927852 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone (400 mg/day for 4 weeks, then 200 mg/day)
Number of subjects: 101
Study 1927852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 1927852 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 101
Study 1927852 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone (with >75% reduction in ectopy)
Number of subjects: 101
Study 1927852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with <=75% ectopic suppression)
Number of subjects: 101
Study 6749270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 82
Study 6749270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 6749270 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 82
Study 31455688 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 g fat
Number of subjects: 0
Study 31455688 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g fat
Number of subjects: 0
Study 31455688 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g fat
Number of subjects: 0
Study 31455688 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g fat
Number of subjects: 0
Study 31455688 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated, monounsaturated, or polyunsaturated fat
Number of subjects: 0
Study 26084869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic management with continuous insulin infusion (target glucose 4.4‐6.1 mmol/l)
Number of subjects: 212
Study 26084869 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic management with intermittent bolus insulin (target glucose <11.1 mmol/l)
Number of subjects: 212
Study 24631949 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA (NETU 300 mg + PALO 0.50 mg) with oral dexamethasone (DEX)
Number of subjects: 413
Study 24631949 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant (APR) regimen + PALO + DEX
Number of subjects: 413
Study 24631949 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA
Number of subjects: 413
Study 22270487 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing nature scenes
Number of subjects: 29
Study 22270487 — intervention group
Group type: COMPARATOR
Intervention: Built scenes
Number of subjects: 29
Study 19604523 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 2 g/d and simvastatin 20 mg
Number of subjects: 80
Study 19604523 — intervention group
Group type: COMPARATOR
Intervention: simvastatin monotherapy 20 mg
Number of subjects: 80
Study 16824762 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training with functional neuromuscular stimulation (FNS) using intramuscular (IM) electrodes
Number of subjects: 37
Study 16824762 — intervention group
Group type: COMPARATOR
Intervention: Gait training without FNS (No-FNS)
Number of subjects: 37
Study 15047004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical BMD (BMD(C)) in hemodialysis patients
Number of subjects: 0
Study 15047004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical bone area, cortical thickness, moment of inertia, polar moment of inertia in hemodialysis patients
Number of subjects: 0
Study 15047004 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hemodialysis
Number of subjects: 0
Study 15047004 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase and intact parathyroid hormone levels
Number of subjects: 0
Study 15047004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged hemodialysis and secondary hyperparathyroidism
Number of subjects: 0
Study 12202469 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 2260
Study 9679526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim (yeast-derived RhuGM-CSF)
Number of subjects: 181
Study 9679526 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (bacteria-derived RhuG-CSF)
Number of subjects: 181
Study 8024910 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ramipril)
Number of subjects: 3
Study 8024910 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1 blocker (metoprolol)
Number of subjects: 3
Study 8024910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2688940 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong therapy with regularly antihypertensive drug taking (n = 50)
Number of subjects: 100
Study 2688940 — intervention group
Group type: COMPARATOR
Intervention: Control group with regularly antihypertensive drug taking only (n = 50)
Number of subjects: 100
Study 30386978 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE Express (2-hour training)
Number of subjects: 147
Study 30386978 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE (1-day training)
Number of subjects: 147
Study 30386978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study 31229087 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid-rich 'matrix-free' formulation (0.8 mg sapotexanthin, 1.2-1.5 mg cryptocapsin)
Number of subjects: 13
Study 31229087 — intervention group
Group type: COMPARATOR
Intervention: Fresh Mamey sapote fruit (0.8 mg sapotexanthin, 1.2-1.5 mg cryptocapsin)
Number of subjects: 13
Study 31229087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test meals (fresh fruit and matrix-free formulation)
Number of subjects: 13
Study 31229087 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid-rich 'matrix-free' formulation
Number of subjects: 13
Study 28042685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stabilization training (LPST)
Number of subjects: 25
Study 28042685 — intervention group
Group type: COMPARATOR
Intervention: Passive automated cycling intervention
Number of subjects: 25
Study 28042685 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 25
Study 25595177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Number of subjects: 12
Study 23286463 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized treatment for insomnia
Number of subjects: 228
Study 21569488 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (CBT) for 12 weeks
Number of subjects: 73
Study 21569488 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 73
Study 19910942 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut breakfast shakes
Number of subjects: 20
Study 19910942 — intervention group
Group type: COMPARATOR
Intervention: Placebo breakfast shakes
Number of subjects: 20
Study 18023662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative nasopharyngeal temperature of 34 degrees C (hypothermic)
Number of subjects: 267
Study 18023662 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative nasopharyngeal temperature of 37 degrees C (normothermic)
Number of subjects: 267
Study 16286127 — intervention group
Group type: EXPERIMENTAL
Intervention: Subinguinal approach
Number of subjects: 99
Study 16286127 — intervention group
Group type: COMPARATOR
Intervention: Inguinal approach
Number of subjects: 99
Study 12032583 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin G (IVIg)
Number of subjects: 0
Study 10190913 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy (10 ppm)
Number of subjects: 108
Study 10190913 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation alone
Number of subjects: 108
Study 7753573 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation cycle ergometry (ESCE) for 30 min
Number of subjects: 6
Study 7753573 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive motion (CPM) for 30 min
Number of subjects: 6
Study 2153881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hines VA Hospital‐based Home Care (HBHC) Program
Number of subjects: 233
Study 2153881 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of HBHC patients
Number of subjects: 233
Study 2153881 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 233
Study 7353752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 6
Study 7353752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after cross-over)
Number of subjects: 6
Study 31792856 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐keto fluprostenol (35 μg/ml)
Number of subjects: 12
Study 31792856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31016812 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicitly described right-skewed survival curve
Number of subjects: 238
Study 31016812 — intervention group
Group type: COMPARATOR
Intervention: Standard communication without right-skewed survival curve
Number of subjects: 238
Study 28275128 — intervention group
Group type: COMPARATOR
Intervention: LNS-LNS
Number of subjects: 3379
Study 28275128 — intervention group
Group type: COMPARATOR
Intervention: IFA-LNS
Number of subjects: 3379
Study 28275128 — intervention group
Group type: COMPARATOR
Intervention: IFA-MNP
Number of subjects: 3379
Study 28275128 — intervention group
Group type: COMPARATOR
Intervention: IFA-Control
Number of subjects: 3379
Study 25519996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive radical prostatectomy (group A)
Number of subjects: 23
Study 25519996 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone (group B)
Number of subjects: 23
Study 24079282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 66
Study 24079282 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (0.5 g/d for 3 weeks, then 1 g/d)
Number of subjects: 66
Study 24079282 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate and ER niacin
Number of subjects: 66
Study 21334569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (alternative SSRI plus CBT)
Number of subjects: 334
Study 21334569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (venlafaxine plus CBT)
Number of subjects: 334
Study 21334569 — intervention group
Group type: COMPARATOR
Intervention: Medication mono-therapy
Number of subjects: 334
Study 19243423 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (40 mg/kg/day for age 1 to <6 months; 50 mg/kg/day for age >or=6 months to <4 years)
Number of subjects: 116
Study 19243423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 17579892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of flaxseed (FS) with soy protein or genistein (GEN) with enterodiol (END) and enterolactone (ENL)
Number of subjects: 0
Study 17579892 — intervention group
Group type: COMPARATOR
Intervention: Soy protein or genistein (GEN) alone
Number of subjects: 0
Study 14758212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue-anchored Integra with postoperative negative-pressure therapy
Number of subjects: 12
Study 14758212 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 12
Study 11282808 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-60 mg)
Number of subjects: 427
Study 11282808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 9153607 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 803
Study 9153607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 7696887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg every 3 weeks)
Number of subjects: 88